Loading
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.
Previous close
$4.11
−$0.37 · -8.26%
After-hours
$4.06
−$0.05 · -1.22%
Oct 8, 4:56 PM ET
Regular session · ET · Market data may be delayed.
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.
Day range
Current $4.11
52-week range
Current $4.11
Regular session · ET · Market data may be delayed.
GoAI Score
Strong sell
Valuation
2
Overpriced
Sentiment
50
Mixed
Risk
88
Extreme Risk
Momentum
22
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.
Day range
Current $4.11
52-week range
Current $4.11
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 32K USD | — | — | 50K USD | 50K USD |
| Cost of goods sold | 424K USD | — | — | — | — |
| Gross profit | −392K USD | — | — | 50K USD | 50K USD |
| Research and development | 340K USD | 278K USD | 1.69M USD | 1.23M USD | 1.23M USD |
| Selling, general, and administrative | 1.98M USD | 1.83M USD | 1.1M USD | 1.05M USD | 1.05M USD |
| Operating expenses | 3.88M USD | 28.75M USD | 4.03M USD | 3.45M USD | 3.45M USD |
| Interest income | 13K USD | 3.95K USD | 13K USD | 24K USD | 165K USD |
| Interest expense | 793K USD | 117.4K USD | 444K USD | 462K USD | 300K USD |
| Depreciation and amortization | 1.15M USD | 1.12M USD | 1.12M USD | 1.11M USD | 1.11M USD |
| Operating income | −4.27M USD | −28.75M USD | −4.03M USD | −3.4M USD | −3.4M USD |
| Net income | −11.84M USD | −24.71M USD | −4.34M USD | −7.05M USD | −7.05M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 23, 2026 | 50:631 | — | — |
Effective Sep 23, 2026
50:631
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
